摘要
用大剂量胸腺肽治疗再生障碍性贫血 (AA )、特发性血小板减少性紫癜 (ITP )的免疫指标变化和临床疗效。将 72例患者随机分为治疗组 ,用胸腺肽 10 0mg/日静滴 ,同时合并使用各自常规治疗方法 ;对照组 :仅使用常规治疗。AA治疗组有效率 5 7 7% ,对照组有效率 45 8% (P >0 0 5 ) ,ITP治疗组有效率 70 % ,对照组有效率 5 0 % (P <0 0 5 ) ,治疗组治疗后IgG、CD3、CD4、CD4/CD8、NK细胞活性、IL 6均明显高于治疗前 (P <0 0 5 )。胸腺肽可调节T淋巴细胞功能 ,间接调节B淋巴细胞 ,增强机体抵抗力 ,提高ITP及部分AA的疗效 ,且无明显副反应 ,大剂量静滴配合常规方法治疗AA、ITP是一种安全且有效的方法。
To evaluate the clinical implications of high dose treatment of thymoxine for haemopoietic disorders,the immunological criteria of 72 patients with aplastic anemia (AA) and idiopathic thrombocytopenia purpura (ITP) were observed In all cases,thymoxine,100mg per day,was given by intravenous drips,and the routine methods of treatment were to be used as control The efficacy rates of the therapeutic group and control group in AA patients were 57 7% and 45 8% respectively;while in ITP patients,those were 70% and 50% respectively The immunological criteria such as immunoglobulin (IgG,IgA,IgM) levels,CD3,CD4,CD8 positive cell percentages,CD4/CD8 ratio value and NK cell activities were all elevated in comparison to those before the treatment It is likely that thymoxine can regulate the functions of T lymphocytes,and improve the therapeutic efficacy in ITP and AA patients.
出处
《上海免疫学杂志》
CAS
CSCD
北大核心
2000年第4期230-232,共3页
Shanghai Journal of Immunology
